The on-demand webinars listed below include those produced by GenomeWeb as well as prerecorded webinars from our sponsors.

To download webinars, select those of interest and hit the "next" button at the bottom of the page.

Webinar Library

PicoPLEX DNA-Seq: Single Cell Sequencing, Theory and Applications
Thu, 02/27/2014 - 02:00
In this archived webinar, recorded Feb. 19, 2014, two speakers outline applications of Rubicon Genomics' PicoPLEX DNA-seq single cell library preparation kit. Jeramiah Smith, assistant professor of biology at the University of Kentucky, discusses the use of PicoPLEX DNA-seq for de novo sequencing of single amphibian chromosomes, while John Langmore, co-founder and chief scientific officer of Rubicon, details the use of PicoPLEX DNA-seq for aneuploidy, CNV, and STR testing of single human cancer and reproductive cells.

Speakers: Jeramiah Smith, Assistant Professor of Biology, University of Kentucky; and John Langmore, Co-Founder and Chief Scientific Officer, Rubicon Genomics

Sponsor: Rubicon Genomics

Recording Date: 2/19/2014

Recording Time: 1 hour

Quantitative Profiling of the Intrinsic Pathway of Apoptosis in Tumor Tissue using Myriad RBM’s Multiplex ApoptosisMAP
Mon, 12/30/2013 - 02:00
This archived webinar, recorded Nov. 22, 2013, provides an overview of Myriad RBM’s quantitative ApoptosisMAP, a multiplexed immunoassay service that provides quantitative measurements of 14 intra-cellular regulators and mediators of apoptosis, including the Bcl family of anti-apoptotic heterodimers. Dominic Eisinger, director of strategic development at Myriad RBM, discusses the utility of ApoptosisMAP for identifying responders to apoptosis inducers or other chemotherapeutic regimes.

Speaker: Dominic Eisinger, Director of Strategic Development, Myriad RBM

Sponsor: Myriad RBM

Recording Date: 11/22/2013

Recording Time: 45 minutes

Rapidly Identify Drug Repurposing Opportunities for New Cancer Therapies
Fri, 11/08/2013 - 13:00
In this online seminar, recorded June 26, 2013, Ilya Shmulevich, a professor at the Institute for Systems Biology, discusses how his team has used big data graph analytics to identify thousands of drug repurposing opportunities. Specifically, the ISB researchers combined MedLine literature references with data from the Cancer Genome Atlas, Uniprot, and Pfam together with their own sequencing and gene expression data in a study that identified a candidate drug for repurposing in breast cancer.

Speaker: Ilya Shmulevich, Professor, Institute for Systems Biology

Sponsor: YarcData

Recording Date: June 26, 2013

Pan-Microbial Diagnosis & Discovery Using Next-Generation Sequencing
Fri, 11/08/2013 - 02:00
In this webinar, recorded Oct. 9, 2013, Charles Chiu, an assistant professor at the University of California, San Francisco, discusses the development and validation of a next-generation sequencing-based assay for pan-microbial diagnosis. The assay has sensitivity of 10 to 100 viral copies per milliliter, with a turnaround time of less than 24 hours. Chiu also provides examples of the impact of NGS for microbial identification in clinical and public health settings.

Speaker: Charles Chiu, Assistant Professor of Laboratory Medicine & Medicine, Infectious Diseases, UCSF; Director of the UCSF-Abbott Viral Diagnostics & Discovery Center, UCSF China Basin; and Associate Director, USCF Clinical Microbiology Laboratory

Sponsor: Rubicon Genomics

Recording Date: October 9, 2013

Winning Westerns: Tips and Techniques for Improved Western Blotting Workflows
Tue, 11/05/2013 - 12:30
Western blotting is a powerful and sensitive technique used to detect low amounts of proteins in complex samples, or to monitor protein expression and purification by protein blotting and immunodetection. Difficulties with this technique arise from poor protein transfer and antibody performance, both complicated and critical parts to the procedure, but completely optimizable with some key knowledge on membrane and antibody mechanics. Please view this online seminar, recorded Nov. 5, to gain more technical insight on the science and optimization of Western blotting.

The first speaker, Dr. Tim Nadler, is a Western blot veteran. Running hundreds of Western blots per year and assisting with customer technical issues, his group has amassed a wealth of information on this technique. In his presentation, he shares some tips and techniques that may enhance your current capabilities to run "Winning Westerns."

Following his talk, Dr. Natalie Tronson discusses how the use of optimal detection reagents and systems has enabled her to speed up her Western blotting workflow.

Is Next Generation Sequencing Accelerating Your Cancer Drug Development and Clinical Trial Programs?
Thu, 10/03/2013 - 02:00
Next-generation sequencing has emerged as a powerful tool to illuminate "druggable" targets in oncology. Tumor heterogeneity and limitations in DNA quality and yield from formalin-fixed specimens, however, present formidable challenges to routine NGS analysis.

In this webinar, panelists Brian Dougherty and Gary Latham discuss the pre-analytical, analytical, and post-analytical hurdles for targeted NGS, and offer solutions using workflows that provide sensitive and accurate results for both discovery and downstream clinical applications.

The speakers also describe how these methods can accelerate drug development by enabling new insights into cancer biology that can inform targeted therapies and companion diagnostics and by guiding patient stratification and selection in clinical trials.

Genomic Biomarker Development: Considerations for Outsourcing and Validation
Tue, 08/27/2013 - 10:00
Genomic technologies are rapidly being adopted for patient care and clinical trial stratification, but questions remain for many clinical and translational groups as to whether to build these resources in house or to outsource.

Researchers, administrators, and clinicians facing the question of whether to start a lab or simply outsource must consider the fact that clinical certification of a molecular lab and genomic tests is a multi-level process, requiring significant amounts of time and materials. The first speaker in this webinar, Dr. Seth Crosby, provides a short overview of this process.

Meanwhile, biopharma companies are increasingly challenged by scarce resources to conduct genomic biomarker analysis in-house. Following Dr. Crosby's talk, Dr. Sirosh Bokhari presents data from a recent study to validate data across multiple modalities for pipeline decision-making. The study was conducted to investigate the mechanisms of resistance to tyrosine kinase inhibition in non-small cell lung cancer cell lines with activating or resistance-conferring mutations.